1. Regeneron starting late stage trials of coronavirus drug cocktail — Bristol-Myers pays Dragonfly Therapeutics $55M to bring NK cells to neuro diseases — JNJ in $480M-plus deal with Emergent for coronavirus vaccine supply — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Getting Any Better

Discussion in 'EndoChoice' started by anonymous, Dec 14, 2015 at 6:42 AM.

  1. anonymous

    anonymous Guest

    Why the extension delay from BSX to push back acquisition by 2+ weeks?

    Did BSX finally do some due diligence and realize EC is a termite infested POS?
     
  2. anonymous

    anonymous Guest

    No. Boston does this in typical fashion with almost every acquisition. They rush the close date and realize that it has to be pushed back as numerous other legal paperwork has to be done (SEC, etc). The acquisition will go through and without any real major issues.

    My concern is not having anything in formal writing guaranteeing the bonus, any commission or severance if one is offered. Trusting the word of GC and Boston isn't exactly reassuring.
     
  3. anonymous

    anonymous Guest

    i wonder why EC hasn't announced their quarterly earnings call date yet. assuming they want to delay as long as possible to keep the acquisition alive. i'm sure it won't be pretty.
     
  4. anonymous

    anonymous Guest

    You silly troll. I am pretty sure BSC is well aware of the past earnings and have no reason to think the 3rd quarter would be any different. When is the last time you saw a company that has been acquired release the quarterly numbers? BSC is getting a steal (literally stealing it from investors at $8/share) with the products they wanted at EC.

    Speaking of stealing, I haven't heard much about the biggest thief in all of this, Mark Gilreath. Anyone?
     
  5. anonymous

    anonymous Guest

    MG doesn't have the balls to show is face in corporate office. He is currently helping bsx sell fuse off to another company. Once the documents are signed, mark is long gone. Not like that's anything different from the last year anayways.
     
  6. anonymous

    anonymous Guest

    Yes. So if we are lucky, we could either work for Boston Sci or Pentax.
     
  7. anonymous

    anonymous Guest

    The chances of Boston sci retaining sales reps is slim. If I were a gambling man, I'd say maybe 4 sales reps will be retained and leave or termed within a year. I've been down this road before.

    If Pentax buys it (likely), I would assume they only keep a few reps where fuse is currently installed to manage the accounts. I don't see Pentax actively selling fuse for 1-2 years after purchase. Fuse is close to being a damn good product and they have the resources to finish it. Honestly, I really hope they do. The clinical benefits are too good to let die.